EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing

Deepa J Arachchillage, Saravanan Vinayagam, Annie Parsons, Nilanthi Karawitage, Mike Laffan

Seminars in Thrombosis and Hemostasis · 01.11.2026 · 52 (08) · 982-990

DOI: 10.1055/a-2734-2293 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.11.2026. Verfasst von Deepa J Arachchillage und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, United Kingdom. Hauptthemen laut MEDLINE: Heparin, Anticoagulants. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct oral anticoagulants (DOACs), including direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), have transformed anticoagulant management in recent years due to their predictable pharmacodynamics, rapid onset of action, and fixed dosing without the need for routine laboratory monitoring. Unfractionated heparin (UFH) remains the anticoagulant of choice for patients who are acutely unwell and treated in intensive care units due to its short half-life, reversibility, ease of dose titration, and nonrenal dependent excretion. It is therefore not uncommon for an individual's anticoagulation management to require rapid changing from DOAC to UFH. Due to UFH's complex pharmacokinetics, including nonspecific binding to acute phase proteins and dose-dependent clearance, careful laboratory monitoring, generally with activated partial thromboplastin time (APTT) or anti-factor Xa (anti-Xa) activity, is necessary. When transitioning from a DOAC to UFH, overlapping pharmacologic effects can significantly interfere with coagulation assays, particularly if residual DOAC levels persist at the time UFH is initiated. DOACs can prolong the APTT and elevate anti-Xa activity, leading to overestimation of UFH activity, inappropriate dose adjustments, and increased risk of bleeding or thromboembolic events. Here, we examine the laboratory implications of transitioning from DOAC therapy to UFH, with a focus on the performance and interpretation of APTT and anti-Xa assays in the presence of residual DOAC levels and how to overcome the interference of DOAC in UFH monitoring. We suggest an algorithm to follow during this transition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HeparinAnticoagulantsHumansAdministration, OralFactor Xa InhibitorsBlood Coagulation TestsPartial Thromboplastin Time

Substanzen

HeparinAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, United Kingdom.
  • Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • North West London Pathology, Imperial College Healthcare NHS Trust, London, United Kingdom.

Zitieren

APA

Arachchillage, D. J., Vinayagam, S., Parsons, A., Karawitage, N., & Laffan, M. (2026). Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing. Seminars in Thrombosis and Hemostasis, 52(08), 982-990. https://doi.org/10.1055/a-2734-2293

Vancouver

Arachchillage DJ, Vinayagam S, Parsons A, Karawitage N, Laffan M. Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing. Seminars in Thrombosis and Hemostasis. 2026;52(08):982-990. doi:10.1055/a-2734-2293

BibTeX
@article{Arachchillage2026,
  author = {Arachchillage, Deepa J and Vinayagam, Saravanan and Parsons, Annie and Karawitage, Nilanthi and Laffan, Mike},
  title = {Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  volume = {52},
  number = {08},
  pages = {982--990},
  doi = {10.1055/a-2734-2293}
}
Kostenlos starten →